Celexa/Lexapro MDL winds up
Celexa/Lexapro MDL winds up
Introduction
The U.S. District Judge Nathaniel M. Gorton granted Forest Laboratories’ motion for summary judgment on all claims made by the plaintiffs who alleged that the company fraudulently promoted Celexa and Lexapro for pediatric depression. This ruling brings an end to the long-running Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation.
Comments
Latest News
Baltimore Wins $266M in Opioid Case Against Drug Distributors
Categories: Opioids
Baltimore has secured a $266 million victory in its lawsuit against major drug distributors McKesson and Cencora (formerly AmerisourceBergen), accusing them of fueling the…
DOJ Opposes JnJ’s Texas Bankruptcy Move in Talc Lawsuit Cases
Categories: Talcum
The U.S. Department of Justice (DOJ) recently opposed Johnson & Johnson’s latest attempt to use bankruptcy to resolve tens of thousands of…
First Valsartan Bellwether Trial to Focus on Cancer Lawsuits
Categories: Valsartan
The U.S. District Judge overseeing…